GlaxoSmithKline Pakistan Limited
35-Dockyard Road,
West Wharf,
Karachi - 74000,
Pakistan
UAN +92 21 111 475 725
Fax +92 21 3231 4898
www.gsk.com.pk

19th May 2020

The General Manager
Pakistan Stock Exchange
Stock Exchange Building
Stock Exchange Road
Karachi.

Subject: **Material Information**

Dear Sir,

As previously communicated on 24th September 2020, GSK was contacted by regulatory authorities regarding the detection of NDMA in Zantac (Ranitidine) products.

Patient safety remains GSK's absolute priority.

Based on the information received and correspondence with regulatory authorities, GSK made the decision in September 2019 and extended it in October 2019, to initiate a voluntary pharmacy/retail level recall in all markets of Zantac products manufactured using all API sources, as a precautionary action. The recall also applied to all Zantac products manufactured in Pakistan.

GSK has continued to respond to the queries received from the regulatory authorities and to work actively with them to address their concerns. GSK has been conducting investigations into the potential source of the NDMA.

We are, through this letter, informing you about a decision that has been made by GSK to discontinue the manufacture and supply of the Ranitidine brand (" Zantac"). As noted by the European Medicines Agency (EMA), there are alternatives medicines to Ranitidine available.

If you require further information, or have any questions, please don't hesitate to contact us.

Regards,

Syed Azeem Abbas Naqvi
Company Secretary